GlobeImmune announces number of shares for IPO

LOUISVILLE – GlobeImmune Inc., a Louisville-based biopharma, that is developing therapeutic drugs for pancreatic cancer and hepatitis B and C, filed terms with the Securities and Exchange Commission for an initial public offering of stock Tuesday.

GlobeImmune plans to raise $35 million by offering 2.2 million shares at a price range of $15 to $17.

GlobeImmune filed with the SEC in March for the IPO saying it wanted to raise $35 million through an IPO, but at that time did not reveal the price or the number of shares it would make available.

SPONSORED CONTENT

How dispatchable resources enable the clean energy transition

Platte River must prepare for the retirement of 431 megawatts (MW) of dispatchable, coal-fired generation by the end of the decade and address more frequent extreme weather events that can bring dark calms (periods when there is no sun or wind).

The filing on Tuesday did not include a date for the IPO.

In March, the company said it would use the proceeds to continue to work on drugs in clinical trials and prepare its manufacturing plant for clinical trial and commercial scale manufacturing, according to the documents.

GlobeImmune filed for an IPO last June to raise $69 million, but withdrew the plan in October, saying at the time that the market was not sufficiently attractive as a place to raise money.

In February, Louisville-based GlobeImmune raised $7.5 million through SternAegis Ventures, an arm of Aegis Capital Corp. in New York, to pay for ongoing operations.

GlobeImmune is developing therapeutic drugs to treat pancreatic cancer and hepatitis B and C, among other research projects. The company has licensing agreements with Gilead Sciences Inc. (Nasdaq: GILD) in Foster City, Calif., and with Celgene Corp. (Nasdaq: CELG) in Summit, N.J., for drugs under development.

Aegis Capital is the sole bookrunner on the deal.